UBX News and Press, Unity Biotechnology Inc. From 08/12/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Ink Drop / Shutterstock Digital World Acquisition (NASDAQ: DWAC ) stock is sliding on Friday as the company waits for a vote from shareholders to extend its merger window with Truth Social . Truth S...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: everything possible / Shutterstock.com Unity Biotechnology (NASDAQ: UBX ) stock is surging higher on Friday following the release of its earnings report for the second quarter of 2022 . That report st...

Unity Biotechnology press release ( NASDAQ: UBX ): Q2 GAAP EPS of -$0.19 beats by $0.10 . Revenue of $0.24M. Cash, cash equivalents and marketable securities totaled $64.5 million as of June 30, 2022, compared with $79.2 million as of March 31, 2022. UNITY beli...

The shares of Unity Biotechnology ( NASDAQ: UBX ) jumped ~93% in the pre-market Friday after the clinical-stage biotech said that its lead product candidate UBX1325 demonstrated a statistically significant treatment effect in patients with diabetic macular edema (DME) in a...

- Announced Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection in subjects led to statistically significant and clinically meaningful improvement in BCVA and CST with favorable safety profile at 12 and 18 weeks - - Near-Ter...

A single injection of UBX1325 led to a progressive, statistically significant, and clinically meaningful improvement in mean Best Corrected Visual Acuity (BCVA) at 12- and 18-weeks compared to sham treatment UBX1325 treatment also stabilized retinal structure, as measured by centr...

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host an investor call to discuss lead program, UBX1325 on Friday,...

SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that 24-week clinical data results from the Phase 1 st...

SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Michael Samar, current chief financial officer at Assembly Bio, ...

SOUTH SAN FRANCISCO, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will provide a corporate update and ...